US6004925A
(en)
*
|
1997-09-29 |
1999-12-21 |
J. L. Dasseux |
Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
|
US6037323A
(en)
*
|
1997-09-29 |
2000-03-14 |
Jean-Louis Dasseux |
Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
|
US6046166A
(en)
*
|
1997-09-29 |
2000-04-04 |
Jean-Louis Dasseux |
Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
|
US6410802B1
(en)
|
1999-04-01 |
2002-06-25 |
Esperion Therapeutics, Inc. |
Methods for synthesizing ether compounds and intermediates therefor
|
US20090017069A1
(en)
*
|
2000-06-29 |
2009-01-15 |
Lipid Sciences, Inc. |
SARS Vaccine Compositions and Methods of Making and Using Them
|
US7407663B2
(en)
*
|
2000-06-29 |
2008-08-05 |
Lipid Sciences, Inc. |
Modified immunodeficiency virus particles
|
US7439052B2
(en)
*
|
2000-06-29 |
2008-10-21 |
Lipid Sciences |
Method of making modified immunodeficiency virus particles
|
US7407662B2
(en)
*
|
2000-06-29 |
2008-08-05 |
Lipid Sciences, Inc. |
Modified viral particles with immunogenic properties and reduced lipid content
|
AUPQ846900A0
(en)
*
|
2000-06-29 |
2000-07-27 |
Aruba International Pty Ltd |
A vaccine
|
US8568766B2
(en)
|
2000-08-24 |
2013-10-29 |
Gattadahalli M. Anantharamaiah |
Peptides and peptide mimetics to treat pathologies associated with eye disease
|
US7144862B2
(en)
*
|
2000-08-24 |
2006-12-05 |
The Regents Of The University Of California |
Orally administered peptides to ameliorate atherosclerosis
|
US7166578B2
(en)
|
2000-08-24 |
2007-01-23 |
The Regents Of The University Of California |
Orally administered peptides synergize statin activity
|
US7723303B2
(en)
*
|
2000-08-24 |
2010-05-25 |
The Regents Of The University Of California |
Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
|
US6664230B1
(en)
*
|
2000-08-24 |
2003-12-16 |
The Regents Of The University Of California |
Orally administered peptides to ameliorate atherosclerosis
|
US7148197B2
(en)
*
|
2000-08-24 |
2006-12-12 |
The Regents Of The University Of California |
Orally administered small peptides synergize statin activity
|
AU2007237157B2
(en)
*
|
2000-08-24 |
2009-04-09 |
The Regents Of The University Of California |
Peptides that ameliorate atherosclerosis
|
US7199102B2
(en)
|
2000-08-24 |
2007-04-03 |
The Regents Of The University Of California |
Orally administered peptides synergize statin activity
|
DE10051983A1
(de)
*
|
2000-10-20 |
2002-06-13 |
Beate Kehrel |
Inhibierung der pathogenen Wirkung oxidierter Proteine
|
WO2002062207A2
(en)
|
2001-01-02 |
2002-08-15 |
The Cleveland Clinic Foundation |
Myeloperoxidase, a risk indicator for cardiovascular disease
|
US20050089932A1
(en)
*
|
2001-04-26 |
2005-04-28 |
Avidia Research Institute |
Novel proteins with targeted binding
|
US7217785B2
(en)
*
|
2001-05-09 |
2007-05-15 |
The Regents Of The University Of California |
Cysteine-containing peptides having antioxidant properties
|
WO2003000372A2
(en)
*
|
2001-06-25 |
2003-01-03 |
Lipid Sciences, Inc. |
Systems and methods using multiple solvents for the removal of lipids from fluids
|
CA2451633C
(en)
*
|
2001-06-25 |
2010-11-30 |
Lipid Sciences, Inc. |
Systems and methods using a solvent for the removal of lipids from fluids
|
US6991727B2
(en)
*
|
2001-06-25 |
2006-01-31 |
Lipid Sciences, Inc. |
Hollow fiber contactor systems for removal of lipids from fluids
|
EP1409108A4
(de)
*
|
2001-06-25 |
2007-11-14 |
Lipid Sciences Inc |
Hohlfaserberührungssysteme zur entfernung von lipiden aus fluiden
|
US20060060520A1
(en)
*
|
2001-06-25 |
2006-03-23 |
Bomberger David C |
Systems and methods using a solvent for the removal of lipids from fluids
|
CA2461702A1
(en)
*
|
2001-09-28 |
2003-04-03 |
Esperion Therapeutics, Inc. |
Methods and apparatus for extrusion of vesicles at high pressure
|
US8119590B2
(en)
*
|
2001-09-28 |
2012-02-21 |
Cedars-Sinai Medical Center |
Prevention and treatment of restenosis by local administration of drug
|
US6930085B2
(en)
|
2002-04-05 |
2005-08-16 |
The Regents Of The University Of California |
G-type peptides to ameliorate atherosclerosis
|
US20040009216A1
(en)
*
|
2002-04-05 |
2004-01-15 |
Rodrigueza Wendi V. |
Compositions and methods for dosing liposomes of certain sizes to treat or prevent disease
|
US20100204103A1
(en)
*
|
2002-05-08 |
2010-08-12 |
The Regents Of The University Of California |
Helical synthetic peptides that stimulate cellular cholesterol efflux
|
US7691965B2
(en)
*
|
2002-05-08 |
2010-04-06 |
The Regents Of The University Of California |
Helical synthetic peptides that stimulate cellular cholesterol efflux
|
CA2486127C
(en)
*
|
2002-05-17 |
2014-03-11 |
Esperion Therapeutics, Inc. |
Method of treating dyslipidemic disorders
|
CA2485989A1
(en)
*
|
2002-05-17 |
2003-11-27 |
Esperion Therapeutics, Inc. |
Methods and compositions for the treatment of ischemic reperfusion
|
EP1545576A2
(de)
*
|
2002-07-30 |
2005-06-29 |
Esperion Therapeutics Inc. |
Verfahren zur verwendung von nichthumanem tierischem apoliprotein a-i protein
|
JP2005538148A
(ja)
*
|
2002-08-26 |
2005-12-15 |
リピド サイエンスィズ インコーポレイテッド |
脱脂タンパク質粒子を使用したアルツハイマー病治療
|
ES2594340T3
(es)
|
2003-01-23 |
2016-12-19 |
Esperion Therapeutics Inc. |
Compuestos de hidroxilo y composiciones para el control del colesterol y utilizaciones correspondientes
|
EP1615954A2
(de)
*
|
2003-04-22 |
2006-01-18 |
Avanir Pharmaceuticals |
Mediatoren des umgekehrten cholesterintransports zur behandlung von hypercholesterinämie
|
AU2004260632A1
(en)
*
|
2003-07-03 |
2005-02-10 |
Lipid Sciences Inc. |
Methods and apparatus for creating particle derivatives of HDL with reduced lipid content
|
US7393826B2
(en)
|
2003-07-03 |
2008-07-01 |
Lipid Sciences, Inc. |
Methods and apparatus for creating particle derivatives of HDL with reduced lipid content
|
US7459286B1
(en)
*
|
2003-10-22 |
2008-12-02 |
The Cleveland Clinic Foundation |
Assessing the risk of a major adverse cardiac event in patients with chest pain
|
US6960803B2
(en)
*
|
2003-10-23 |
2005-11-01 |
Silicon Storage Technology, Inc. |
Landing pad for use as a contact to a conductive spacer
|
ATE546734T1
(de)
*
|
2003-12-05 |
2012-03-15 |
Cleveland Clinic Foundation |
Risikomarker für eine herzkreislaufkrankheit
|
EP1699527A1
(de)
*
|
2004-01-02 |
2006-09-13 |
Advanced Cardiovascular Systems, Inc. |
Mit lipoprotein hoher dichte beschichtete medizinprodukte
|
EP1732383A4
(de)
*
|
2004-04-06 |
2007-05-02 |
Cedars Sinai Medical Center |
Vorbeugung und behandlung von gefässerkrankungen mit rekombinanten adeno assoziierten virusvektoren, die für apolipoprotein a-i und apolipoprotein a-i milano kodieren
|
US7378396B2
(en)
*
|
2004-08-11 |
2008-05-27 |
The Cleveland Clinic Foundation |
Therapeutic agents and methods for cardiovascular disease
|
US20060205669A1
(en)
*
|
2004-09-16 |
2006-09-14 |
The Regents Of The University Of California |
G-type peptides and other agents to ameliorate atherosclerosis and other pathologies
|
WO2006049597A1
(en)
*
|
2004-10-27 |
2006-05-11 |
Avanir Pharmaceuticals |
Amino acid-derived compounds as modulators of the reverse cholesterol transport
|
CN101115496B
(zh)
|
2004-12-06 |
2012-03-07 |
加州大学评议会 |
改善微动脉的结构和功能的方法
|
WO2006069371A1
(en)
*
|
2004-12-22 |
2006-06-29 |
Baylor College Of Medicine |
A method of plasma lipidation to prevent, inhibit and/or reverse atherosclerosis
|
US7759315B2
(en)
|
2005-03-09 |
2010-07-20 |
Csl Behring Ag |
Treatment of inflammatory conditions of the intestine
|
US8206750B2
(en)
|
2005-03-24 |
2012-06-26 |
Cerenis Therapeutics Holding S.A. |
Charged lipoprotein complexes and their uses
|
US20080293639A1
(en)
*
|
2005-04-29 |
2008-11-27 |
The Regents Of The University Of California |
Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
|
MX2007013430A
(es)
*
|
2005-04-29 |
2008-03-19 |
Univ California |
Peptidos y peptidos mimeticos para tratar patologias caracterizadas por una respuesta inflamatoria.
|
NZ565955A
(en)
|
2005-08-22 |
2011-08-26 |
Melior Pharmaceuticals I Inc |
Methods and formulations for modulating lyn kinase activity and treating related disorders
|
US20070254832A1
(en)
*
|
2006-02-17 |
2007-11-01 |
Pressler Milton L |
Methods for the treatment of macular degeneration and related eye conditions
|
MX2008015337A
(es)
*
|
2006-06-01 |
2009-11-26 |
Inst Cardiologie Montreal |
Metodo y compuesto para el tratamiento de estenosis valvular.
|
US20080227686A1
(en)
*
|
2006-06-16 |
2008-09-18 |
Lipid Sciences, Inc. |
Novel Peptides that Promote Lipid Efflux
|
EP2041174A2
(de)
*
|
2006-06-16 |
2009-04-01 |
Lipid Sciences, Inc. |
Neue, den lipidausstrom fördernde peptide
|
US20080206142A1
(en)
*
|
2006-06-16 |
2008-08-28 |
Lipid Sciences, Inc. |
Novel Peptides That Promote Lipid Efflux
|
EP2049137A4
(de)
|
2006-08-08 |
2013-05-01 |
Univ California |
Salicylanilide als verstärker der oralen freisetzung therapeutischer peptide
|
WO2008039843A2
(en)
*
|
2006-09-26 |
2008-04-03 |
Lipid Sciences, Inc. |
Novel peptides that promote lipid efflux
|
US8541236B2
(en)
*
|
2006-12-08 |
2013-09-24 |
University Of Washington |
Mutant apolipoprotein A-1 polypeptide with increased resistance to oxidation and reactive carbonyls
|
WO2008094905A2
(en)
*
|
2007-01-29 |
2008-08-07 |
Lipid Sciences, Inc. |
Encapsulated hdl mimetic peptides
|
CA3021932C
(en)
*
|
2007-01-31 |
2020-12-15 |
Jds Therapeutics, Llc |
Use of chromium histidinate for treatment of cardiometabolic disorders
|
NZ579227A
(en)
*
|
2007-02-20 |
2012-11-30 |
Melior Pharmaceuticals I Inc |
Methods of identifying activators of lyn kinase
|
EP1964571B1
(de)
|
2007-03-01 |
2012-05-02 |
CSL Limited |
Behandlung von endothelialer Dysfunktion bei Diabetes-Patienten
|
CA2681158C
(en)
|
2007-03-13 |
2018-09-18 |
Nutrition 21, Inc. |
Methods and compositions for the sustained release of chromium
|
WO2009002867A2
(en)
|
2007-06-26 |
2008-12-31 |
Nutrition 21, Inc. |
Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
|
BRPI0813167A2
(pt)
*
|
2007-07-23 |
2014-12-23 |
Melior Discovery Inc |
Usos de uma composição e de um agente para modular a atividade e/ou a expressão de irs-1 e/ou akt, e, composto
|
US8557767B2
(en)
|
2007-08-28 |
2013-10-15 |
Uab Research Foundation |
Synthetic apolipoprotein E mimicking polypeptides and methods of use
|
AU2008296478B9
(en)
|
2007-08-28 |
2015-03-19 |
The Uab Research Foundation |
Synthetic apolipoprotein E mimicking polypeptides and methods of use
|
US9173890B2
(en)
*
|
2007-09-20 |
2015-11-03 |
Abbott Cardiovascular Systems Inc. |
Sustained release of Apo A-I mimetic peptides and methods of treatment
|
US8101565B2
(en)
*
|
2007-09-20 |
2012-01-24 |
Abbott Cardiovascular Systems Inc. |
Sustained release of Apo A-I mimetic peptides and methods of treatment
|
US7985728B1
(en)
|
2007-09-20 |
2011-07-26 |
Abbott Cardiovascular Systems Inc. |
Sustained release of Apo A-I mimetic peptides and methods of treatment
|
US8044021B2
(en)
|
2007-09-20 |
2011-10-25 |
Abbott Cardiovascular Systems Inc. |
Sustained release of apo A-I mimetic peptides and methods of treatment
|
US7985727B1
(en)
|
2007-09-20 |
2011-07-26 |
Abbott Cardiovascular Systems Inc. |
Apo A-I mimetic peptides and methods of treatment
|
US8552184B2
(en)
*
|
2008-07-03 |
2013-10-08 |
Melior Pharmaceuticals I, Inc. |
Compounds and methods for treating disorders related to glucose metabolism
|
US8241861B1
(en)
|
2008-07-08 |
2012-08-14 |
Insilicos, Llc |
Methods and compositions for diagnosis or prognosis of cardiovascular disease
|
EP3207944B1
(de)
|
2008-11-10 |
2020-01-15 |
Arbutus Biopharma Corporation |
Neuartige lipide und zusammensetzungen zur verabreichung von therapeutika
|
EP3243504A1
(de)
|
2009-01-29 |
2017-11-15 |
Arbutus Biopharma Corporation |
Verbesserte lipidformulierung
|
NZ594516A
(en)
|
2009-02-16 |
2012-12-21 |
Cerenis Therapeutics Holding Sa |
Apolipoprotein a-i mimics
|
JP6032724B2
(ja)
|
2009-03-12 |
2016-11-30 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
脂質製剤組成物およびEg5遺伝子とVEGF遺伝子の発現を阻害する方法
|
JP5769701B2
(ja)
|
2009-05-05 |
2015-08-26 |
テクミラ ファーマシューティカルズ コーポレイションTekmira Pharmaceuticals Corporation |
脂質組成物
|
AU2010259984B2
(en)
|
2009-06-10 |
2017-03-09 |
Arbutus Biopharma Corporation |
Improved lipid formulation
|
AP2015008874A0
(en)
|
2009-08-14 |
2015-11-30 |
Alnylam Pharmaceuticals Inc |
Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
|
CN102753576A
(zh)
*
|
2009-09-30 |
2012-10-24 |
首尔大学教产学协力团 |
载脂蛋白a-1模拟肽以及包含其的用于治疗高血脂及高血脂相关疾病的治疗剂
|
US10525152B2
(en)
|
2009-10-09 |
2020-01-07 |
Signablok, Inc. |
Methods and compositions for targeted imaging
|
US10894098B2
(en)
|
2012-04-09 |
2021-01-19 |
Signablok, Inc. |
Methods and compositions for targeted imaging
|
WO2011071860A2
(en)
|
2009-12-07 |
2011-06-16 |
Alnylam Pharmaceuticals, Inc. |
Compositions for nucleic acid delivery
|
AU2010330814B2
(en)
|
2009-12-18 |
2017-01-12 |
Acuitas Therapeutics Inc. |
Methods and compositions for delivery of nucleic acids
|
WO2011139911A2
(en)
|
2010-04-29 |
2011-11-10 |
Isis Pharmaceuticals, Inc. |
Lipid formulated single stranded rna
|
WO2011143362A1
(en)
|
2010-05-11 |
2011-11-17 |
Esperion Therapeutics, Inc. |
Dimeric oxidation-resistant apolipoprotein a1 variants
|
EP3254672A1
(de)
|
2010-06-03 |
2017-12-13 |
Alnylam Pharmaceuticals, Inc. |
Biologisch abbaubare lipide zur freisetzung von wirkstoffen
|
US20130323269A1
(en)
|
2010-07-30 |
2013-12-05 |
Muthiah Manoharan |
Methods and compositions for delivery of active agents
|
WO2012016188A2
(en)
|
2010-07-30 |
2012-02-02 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for delivery of active agents
|
EP2611419A2
(de)
|
2010-08-30 |
2013-07-10 |
F.Hoffmann-La Roche Ag |
Verfahren zur herstellung eines tetranectin-apolipoprotein-a1-partikels, dieses partikel selbst und seine verwendung
|
CN103370054A
(zh)
|
2010-11-09 |
2013-10-23 |
阿尔尼拉姆医药品有限公司 |
用于抑制Eg5和VEGF基因的表达的脂质配制的组合物和方法
|
DK3202760T3
(da)
|
2011-01-11 |
2019-11-25 |
Alnylam Pharmaceuticals Inc |
Pegylerede lipider og deres anvendelse til lægemiddelfremføring
|
CN105288589A
(zh)
|
2011-02-07 |
2016-02-03 |
塞勒尼斯医疗控股公司 |
脂蛋白复合物及其制备和用途
|
EP2680861B1
(de)
|
2011-03-01 |
2022-05-04 |
Nutrition 21, LLC |
Zusammensetzungen enthaltend insulin und chrom zur behandlung und vorbeugung von diabetes und hypoglykämie und verwandten krankheiten
|
EP3456317A1
(de)
|
2011-09-27 |
2019-03-20 |
Alnylam Pharmaceuticals, Inc. |
Substituierte di-aliphatic pegylierte lipide
|
US20150190396A1
(en)
|
2011-12-12 |
2015-07-09 |
Melior Pharmaceuticals l, Inc. |
Treatment of type i and type ii diabetes
|
CN103073646A
(zh)
*
|
2012-03-13 |
2013-05-01 |
华中科技大学 |
一种运载蜂毒肽的多肽、运载蜂毒肽的纳米颗粒及其应用
|
CN105050614B
(zh)
|
2013-03-15 |
2019-04-05 |
加利福尼亚大学董事会 |
刺激胆固醇流出的具有降低的毒性的肽
|
EP2853259A1
(de)
|
2013-09-30 |
2015-04-01 |
Université Pierre et Marie Curie (Paris 6) |
Rekonstituierte hochdichte Lipoproteinzusammensetzung und Verwendungen davon
|
SG11201609084QA
(en)
|
2014-05-02 |
2016-11-29 |
Cerenis Therapeutics Holding Sa |
Hdl therapy markers
|
WO2016011049A2
(en)
*
|
2014-07-14 |
2016-01-21 |
Schwendeman Anna |
Compositions and methods for disease treatment using nanoparticle delivered compounds
|
CN107074923B
(zh)
|
2014-07-31 |
2021-08-03 |
Uab研究基金会 |
Apoe模拟肽及对清除血浆胆固醇的较高效力
|
US10307491B2
(en)
|
2015-01-30 |
2019-06-04 |
The Regents Of The University Of Michigan |
Liposomal particles comprising biological molecules and uses thereof
|
CN107530307A
(zh)
|
2015-03-13 |
2018-01-02 |
艾斯柏伦治疗公司 |
包含etc1002和依泽替米贝的固定剂量组合和制剂以及治疗心血管疾病或降低心血管疾病风险的方法
|
MA41793A
(fr)
|
2015-03-16 |
2018-01-23 |
Esperion Therapeutics Inc |
Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire
|
BR112017020491A2
(pt)
|
2015-03-25 |
2018-07-17 |
The Regents Of The University Of Michigan |
composições e métodos para distribuição de agentes de biomacromolécula.
|
EP3413900A1
(de)
|
2016-02-11 |
2018-12-19 |
Nutrition 21, LLC |
Chromhaltige zusammensetzungen zur verbesserung der gesundheit und fitness
|
US10821133B2
(en)
|
2017-12-28 |
2020-11-03 |
Hdl Therapeutics, Inc. |
Methods for preserving and administering pre-beta high density lipoprotein extracted from human plasma
|
WO2018191166A1
(en)
|
2017-04-10 |
2018-10-18 |
Melior Pharmaceuticals I, Inc. |
Treatment of adipocytes
|
US20190048049A1
(en)
|
2017-08-10 |
2019-02-14 |
Cerenis Therapeutics Holding Sa |
Cargomers
|
CN111868232B
(zh)
|
2017-11-22 |
2024-05-28 |
Hdl治疗公司 |
用于对血浆处理系统的流体回路进行灌注的系统和方法
|
CN112437765A
(zh)
|
2019-06-21 |
2021-03-02 |
艾斯柏伦治疗公司 |
贝派地酸的盐形式及其使用方法
|
WO2021209823A1
(en)
|
2020-04-16 |
2021-10-21 |
Abionyx Pharma Sa |
Methods for treating acute conditions using lipid binding protein- based complexes
|
IL301769A
(en)
|
2020-10-01 |
2023-05-01 |
Abionyx Pharma Sa |
Methods for treating eye diseases by using complexes based on lipid-binding proteins
|
IL307670A
(en)
|
2021-04-15 |
2023-12-01 |
Abionyx Pharma Sa |
Use of lipid-binding protein-based complexes in organ preservation solutions
|
WO2023194798A1
(en)
|
2022-04-06 |
2023-10-12 |
Abionyx Pharma Sa |
Methods for treating leukocytosis, endothelial dysfunction and carditis using lipid binding protein-based complexes
|
WO2023194797A1
(en)
|
2022-04-06 |
2023-10-12 |
Abionyx Pharma Sa |
Methods for treating eye diseases using lipid binding protein-based complexes
|
WO2023237935A2
(en)
|
2022-06-10 |
2023-12-14 |
Abionyx Pharma Sa |
Methods for treating acute conditions using lipid binding protein-based complexes
|
WO2023237927A2
(en)
|
2022-06-10 |
2023-12-14 |
Abionyx Pharma Sa |
Methods for treating hyperinflammatory conditions using lipid binding protein -based complexes
|